Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?

Lignende værker

• The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
  af: De Santo, Irene, et al.
  Udgivet: (2019)
• Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
  af: Rossi, Lorenzo, et al.
  Udgivet: (2019)
• Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
  af: Rossi, Lorenzo, et al.
  Udgivet: (2018)
• The role of abemaciclib in treatment of advanced breast cancer
  af: McCartney, Amelia, et al.
  Udgivet: (2018)
• Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
  af: Galardi, Francesca, et al.
  Udgivet: (2021)